×
Year in Review: Psoriatic Arthritis
https://www.medpagetoday.com/rheumatology/arthritis/83077

Nov 1st, 2019 - Major new insights into the treatment of psoriatic arthritis (PsA) dominated the headlines during the past year, with a head-to-head trial comparing interleukin (IL)-17A inhibition with tumor necrosis factor (TNF) blockade, another study considering whether methotrexate can improve outcomes with anti-TNF therapy in PsA, and an investigation into the effects of biologic therapy on bone. These br...

Discharge After Knee Replacement: Race Matters
https://www.medpagetoday.com/surgery/orthopedics/83076

Nov 1st, 2019 - African-American patients who underwent total knee arthroplasty were more likely than whites to be discharged to an inpatient or skilled nursing facility after the procedure, and also to be readmitted to an acute care hospital within 90 days, a large retrospective cohort study found. Among 107,768 individuals who had knee replacement surgeries, the likelihood of being discharged to an inpatient...

Frailty Predicts Damage in SLE
https://www.medpagetoday.com/rheumatology/lupus/82915

Oct 23rd, 2019 - A frailty index helped predict future disease damage in patients with systemic lupus erythematosus (SLE), an international group of researchers and experts reported. On a multivariable analysis, each 0.05-point increase in the baseline frailty index developed by the Systemic Lupus International Collaborating Clinics (SLICC) group was associated with a 20% higher rate of later damage accumulatio...

Treatment Still Falls Short in Majority With RA
https://www.medpagetoday.com/rheumatology/arthritis/82887

Oct 23rd, 2019 - More than half of patients with rheumatoid arthritis (RA) with persistent moderate-to-high disease activity after 6 months of treatment with a conventional disease-modifying anti-rheumatic drug (DMARD) did not have their therapy escalated, a U.S. registry study found. Among 409 patients enrolled in the Corrona registry from 2014 to 2018 with moderate-to-high disease activity at baseline, and wh...

Joint Injections: Are They Worth the Risk?
https://www.medpagetoday.com/rheumatology/arthritis/82753

Oct 15th, 2019 - Intra-articular injections of corticosteroids for relief of the pain of hip or knee osteoarthritis (OA) may have adverse long-term consequences, researchers suggested. These injections are commonly performed and have been "conditionally" recommended by the American College of Rheumatology and "should be considered," according to the Osteoarthritis Research Society International. The American Ac...

Consider centralized pain in patients with rheumatic disease
https://www.mdedge.com/surgery/article/209664/pain/consider-centralized-pain-patients-rheumatic-disease/page/0/1?channel=237

Oct 8th, 2019 - Opioid responsiveness To examine whether fibromyalgia survey results correlate with outcomes after knee and hip arthroplasty, Dr. Clauw and colleagues conducted a prospective, observational cohort study that included approximately 500 people.

We Have a Winner: Head-to-Head Study Compares Biologics for PsA
https://www.medpagetoday.com/rheumatology/arthritis/82499

Sep 30th, 2019 - Ixekizumab (Taltz) was superior to adalimumab (Humira) at 24 weeks in an open-label, ongoing, multicenter head-to-head trial evaluating both skin and joint symptoms in psoriatic arthritis (PsA), investigators reported. On the primary endpoint of the simultaneous achievement of a 50% improvement on the articular criteria of the American College of Rheumatology (ACR50) and a 100% clearing on the ...

ACR 2018 Highlights Quiz
https://www.rheumatologynetwork.com/acr/acr-2018-highlights-quiz
Robert, L.

Jan 3rd, 2019 - Test your knowledge of the featured topics and findings reported at rheumatology’s annual educational gathering

Positive results reported for ixekizumab versus adalimumab in PsA
https://www.mdedge.com/rheumatology/article/191507/psoriatic-arthritis/positive-results-reported-ixekizumab-versus?channel=39313
Lucas Franki

Dec 19th, 2018 - Eli Lilly and Co. has announced positive results from the phase 3b/4, multicenter, randomized, open-label, parallel-group SPIRIT-H2H trial, which compared ixekizumab (Taltz) with adalimumab (Humira) in patients with psoriatic arthritis who had previously not taken a biologic disease-modifying antirheumatic drug.

Natural killer cells implicated in psoriatic arthritis
https://www.mdedge.com/rheumatology/article/191506/psoriatic-arthritis/natural-killer-cells-implicated-psoriatic-arthritis?channel=39313
Bruce Jancin

Dec 19th, 2018 - CHICAGO – A specific type of natural killer cell has for the first time been implicated as playing a key contributory role in the development of psoriatic arthritis in patients with psoriasis. Bruce Jancin/MDedge News Dr.

Weekly Full-Body Massage Improves Short-term Knee OA Pain
https://www.medscape.com/viewarticle/906793

Dec 18th, 2018 - A weekly full-body massage may be an effective way to help patients with knee osteoarthritis (OA) manage pain, data from a randomized trial show. "Osteoarthritis is a leading cause of disability and affects more than 30 million people in America," lead author Adam Perlman, MD, program director of the Leadership Program in Integrative Healthcare at Duke University School of Medicine, Durham, Nor...

Canakinumab reduces arthroplasty rates
https://www.mdedge.com/rheumatology/article/191438/osteoarthritis/canakinumab-reduces-arthroplasty-rates?channel=39313
Bruce Jancin

Dec 18th, 2018 - CHICAGO – Canakinumab, a human monoclonal antibody targeting interleukin-1 beta, was associated with an eye-popping 45% relative risk reduction in the rate of total knee or hip replacement in a prespecified secondary analysis of the landmark CANTOS trial, Matthias Schieker, MD, reported at the annual meeting of the American College of Rheumatology. Bruce Jancin/MDedge News Dr.

How to Teach in the Inpatient Setting
https://www.the-rheumatologist.org/article/how-to-teach-in-the-inpatient-setting/
Collins, T.

Dec 18th, 2018 - Teaching in the inpatient setting can be a tall task, hindered by a lack of time, an unpredictable environment and a variety of learners encountered at different levels. But a few techniques—based mainly on understanding who your students are and how they prefer to learn—can make a big difference, an expert said at the 2018 ACR/ARHP Annual Meeting.

Tips for Navigating Your First Medical Faculty Job
https://www.the-rheumatologist.org/article/tips-for-navigating-your-first-medical-faculty-job/
Collins, T.

Dec 18th, 2018 - Throughout medical training, you have guideposts and guardrails all around you: academic advisors, professors in the classroom, preceptors in the clinic during residency. But once you get a job as a medical faculty member, you’re basically on your own.

Tips for Using Digital Health Tools
https://www.the-rheumatologist.org/article/tips-for-using-digital-health-tools/
Collins, T.

Dec 18th, 2018 - Approximately 200,000 health apps are available through major app stores. Some offer real benefits, said Brennan Spiegel, MD, MSHS, director of health services research at Cedars-Sinai Health System, Los Angeles, Calif. But most, he told attendees at the 2018 ACR/ARHP Annual Meeting, are “rubbish.”

ACR Leaders Discuss E/M Coding Changes, Step Therapy & More
https://www.the-rheumatologist.org/article/acr-leaders-discuss-e-m-coding-changes-step-therapy-more/
Collins, T.

Dec 18th, 2018 - ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals.

Annual Meeting Speakers Review Studies Ranging from Opioids to Fibroblasts
https://www.the-rheumatologist.org/article/annual-meeting-speakers-review-studies-ranging-from-opioids-to-fibroblasts/
Collins, T.

Dec 18th, 2018 - Findings on opioid efficacy, serum urate in osteoarthritis and arthrocentesis headlined the top research of the year discussed in the first half of a session at the 2018 ACR/ARHP Annual Meeting. The second half covered basic science findings, including summaries of new insights into the gender bias in autoimmune diseases, platelet microparticles in scleroderma and fibroblasts in rheumatoid arth...

New insight gained into natural history of interstitial pneumonia with autoimmune features
https://www.mdedge.com/rheumatology/article/191369/lupus-connective-tissue-diseases/new-insight-gained-natural-history?channel=39313
Bruce Jancin

Dec 17th, 2018 - CHICAGO – Patients who meet the criteria for interstitial pneumonia with autoimmune features are more than 14 times more likely to progress to a systemic autoimmune rheumatic disease than are those with idiopathic interstitial lung disease who don’t meet the criteria, Michail Alevizos, MD, reported at the annual meeting of the American College of Rheumatology. Bruce Jancin/MDedge News Dr.

Drug-drug interactions in rheumatology patients on PPIs: An underappreciated problem?
https://www.mdedge.com/internalmedicine/article/191368/rheumatoid-arthritis/drug-drug-interactions-rheumatology-patients?channel=53
Bruce Jancin

Dec 17th, 2018 - CHICAGO – Chronic use of proton pump inhibitors is widespread among patients with rheumatoid arthritis or systemic lupus erythematosus, posing a distinct danger of unwelcome drug-drug interactions affecting the rate and extent of absorption of selected oral antirheumatic drugs, Nicholas Jones, PharmD, said at the annual meeting of the American College of Rheumatology. Of particular interest is.

Rheumatologist prescribing rates predict chronic opioid use in RA patients
https://www.mdedge.com/rheumatology/article/191359/rheumatoid-arthritis/rheumatologist-prescribing-rates-predict-chronic?channel=39313
Sharon Worcester

Dec 17th, 2018 - CHICAGO – A physician’s baseline opioid prescribing rate strongly predicts future chronic opioid use in rheumatoid arthritis patients, an analysis of data from the Consortium of Rheumatology Researchers of North America (Corrona) Rheumatoid Arthritis Registry suggests. sdominick/iStock/Getty Images The baseline 12-month opioid prescribing rate of 148 physicians in the initial cohort varied wide.